Entasis Therapeutics Holdings, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -1.19%569.802.7%$666.62m
ILMNIllumina, Inc. -0.20%319.793.5%$657.13m
AMGNAmgen, Inc. -0.89%229.051.3%$593.89m
ARRYArray BioPharma Inc. 6.20%40.8814.2%$533.21m
GILDGilead Sciences, Inc. -0.45%60.281.0%$504.75m
MRNAModerna, Inc. -1.74%70.070.0%$494.93m
VRTXVertex Pharmaceuticals, Inc. -0.80%212.831.9%$475.82m
IMMUImmunomedics, Inc. 0.09%87.8011.0%$388.12m
NVAXNovavax, Inc. -5.40%93.0596.5%$308.45m
ALXNAlexion Pharmaceuticals, Inc. -3.01%120.272.0%$288.77m
BIIBBiogen, Inc. -0.21%266.561.6%$257.07m
EXASEXACT Sciences Corp. -2.11%100.8520.7%$224.50m
BNTXBioNTech SE -6.99%87.760.0%$209.70m
SRNESorrento Therapeutics, Inc. -2.68%8.001.4%$187.43m
SGENSeagen Inc. 1.23%200.466.0%$172.18m

Company Profile

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.